会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 8. 发明授权
    • CRF antagonistic pyrazolo[4,3-b]pyridines
    • CRF拮抗性吡唑并[4,3-b]吡啶
    • US06613777B1
    • 2003-09-02
    • US09623634
    • 2001-02-20
    • Chen ChenKeith M. WilcoxenCharles Q. HuangMustapha HadduchJames R. McCarthy
    • Chen ChenKeith M. WilcoxenCharles Q. HuangMustapha HadduchJames R. McCarthy
    • A61K3144
    • C07D471/04
    • This invention concerns compounds of formula including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein R1 is C1-6alkyl, NR5R6, OR6 or SR6; R2 is C1-6alkyl, C1-6alkyloxy, or C1-6alkylthio; R3 is Ar1 or Het1; R4 is hydrogen or C1-6alkyl; R5 is hydrogen, C1-8alkyl, mono- or di(C3-6cycloalkyl)methyl, C3-6cycloalkyl, C3-6alkenyl, hydroxyC1-6alkyl, C1-6alkylcarbonyloxyC1-6alkyl, mono- or di(C1-6alkyl)amino-C1-6alkyl or C1-6alkyloxyC1-6alkyl; R6 is C1-8alkyl, mono- or di(C3-6cycloalkyl)methyl, Ar2C1-6alkyl, Ar2oxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, hydroxyC1-6alkyl, C3-6alkenyl, thienylmethyl, furanylmethyl, tetrahydrofuranylmethyl, C1-6alkylthioC1-6alkyl, mono- or di(C1-6alkyl)aminoC1-6alkyl, di(C1-6alkyl)amino, or C1-6alkylcarbonylC1-6alkyl; or R5 and R6 taken together with the nitrogen atom to which they are attached may form a pyrrolidinyl, piperidinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl group, optionally substituted with 1 or 2 substituents each independently selected from C1-6alkyl or C1-6alkyloxyC1-6alkyl; and and Ar1 and Ar2 are each optionally substituted phenyl; and Het1 is optionally substituted pyridinyl; having CRF receptor antagonistic properties; pharmaceutical compositions containing such compounds as active ingredients; methods of treating disorders related to hypersecretion of CRF such as depression, anxiety, substance abuse, by administering an effective amount of a compound of formula (I).
    • 本发明涉及包括其立​​体异构体及其药学上可接受的酸加成盐形式的化合物,其中R 1是C 1-6烷基,NR 5 R 6,OR 6或SR 6; R2是C1-6烷基,C1-6烷氧基或C1-6烷硫基; R3是Ar1或Het1; R4是氢或C1-6烷基; R5是氢,C1-8烷基,一或二(C3-6环烷基)甲基,C3-6环烷基,C3-6烯基,羟基C1-6烷基,C1-6烷基羰基氧基C 1-6烷基,单或二(C1-6烷基)氨基C1- C 1-6烷基或C 1-6烷氧基C 1-6烷基; R 6是C 1-8烷基,单或二(C 3-6环烷基)甲基,Ar 2 C 1-6烷基,Ar 2氧基C 1-6烷基,C 1-6烷氧基C 1-6烷基,羟基C 1-6烷基,C 3-6烯基,噻吩基甲基,呋喃基甲基,四氢呋喃基甲基,C 1-6烷硫基C 1-6烷基 ,单或二(C 1-6烷基)氨基C 1-6烷基,二(C 1-6烷基)氨基或C 1-6烷基羰基C 1-6烷基; 或者R 5和R 6与它们所连接的氮原子一起形成吡咯烷基,哌啶基,高哌啶基,吗啉基或硫代吗啉基,任选地被1或2个独立地选自C 1-6烷基或C 1-6烷氧基C 1-6烷基的取代基取代 ; 并且Ar 1和Ar 2各自为任选取代的苯基; Het1是任选取代的吡啶基; 具有CRF受体拮抗特性; 含有这些化合物作为活性成分的药物组合物; 通过施用有效量的式(I)化合物来治疗与CRF过度分泌有关的疾病的方法,例如抑郁症,焦虑症,药物滥用。